Stock Analysis
BeOne Medicines AG (ONC) Stock Analysis
BeOne Medicines AG (ONC) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
BeOne Medicines AG (ONC) currently has an AIQ Score of 80/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 71/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ONC at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $416.54 |
| AIQ Score | 80/100 |
| Overall View | Very Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $47.36B |
| P/E Ratio (TTM) | 66.97 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $3.38 |
| Revenue (Q3 FY2026) | $1.89B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.68 |
| Volume | 345.46K |
| 52-week range | $253.95-$424.73 |
| RSI 14 | 67.46 |
| 50-Day SMA | $369.18 |
| 200-Day SMA | $327.80 |
| Analyst Price Target | $437.80 |
| Next Earnings | Feb 25, 2027 |
ONCBeOne Medicines AG
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum91
- Value71
- Quality78
- Risk resilience72
- Sentiment—
ONC Stock Analysis Summary
BeOne Medicines AG (ONC) currently has an AIQ Score of 80/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 71/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a very bullish regime, ONC has AIQ Score of 80/100 with Momentum base of 91/100 and fading Value at 71/100. Wait for component alignment before adding exposure.
Momentum (91/100) leads while Value (71/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.14% stock move · ONC classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ONC Bullish or Bearish Right Now?
ONC currently has a very bullish overall setup. Momentum is the strongest factor at 91/100, while Value is weakest at 71/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 78/100.
- - Momentum is constructive at 91/100.
- - Risk Resilience is supportive at 72/100.
- - Price is +12.83% above its 50-day SMA.
- - Analyst target implies +5.10% upside from the latest quote.
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
ONC's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 7 sell votes. ONC's 14-day RSI is 67.46, which places the stock in a constructive momentum range. ONC's beta is 0.68, indicating lower market sensitivity than the broad market.
What Changed in ONC?
The largest recent change in ONC is Momentum moving up by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ONC Outlook?
The current very bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ONC Decision Framework
Public evidence layers, setup checks, and risk context for BeOne Medicines AG.
BeOne Medicines AG (ONC) Stock Analysis
BeOne Medicines AG has an AIQ Score of 80/100 in a Very Bullish regime. Momentum is strongest at 91/100. Beta is 0.68, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ONC is in a Very Bullish AIQ regime with score 80/100. |
| Signal Conflict | The primary conflict is that momentum leads at 91/100 while value lags at 71/100. |
| Factor Evidence | Momentum 91/100 · Value 71/100 · Quality 78/100 · Risk 72/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 91/100.
Momentum is 91/100 and RSI (14) is 67.5.
ONC is in a Very Bullish regime at 80/100.
Risk factor is 72/100 with beta 0.68 and annual volatility 34.16%.
Current conflict: momentum leads at 91/100 while value lags at 71/100.
ONC Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ONC Fundamentals
ONC valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ONC Technical Analysis
ONC technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ONC Stock Catalysts
Track ONC earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ONC Dividend Analysis
ONC dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ONC Financial Data
ONC revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ONC Risk Analysis
ONC volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ONC Stock News
ONC stock news, market tone, recent headlines, and catalyst context.
ONC vs Biotechnology Peers
Current peer cohort: ONC · ORKA · PCVX · PGEN · PRAX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ONC Current stock | 80/100 | 71/100 | 91/100 | 72/100 | 0.42 | 34.16% | Current |
| ORKA Oruka Therapeutics, Inc. | 77/100 | — | 81/100 | 53/100 | 2.29 | 69.09% | ONC vs ORKA |
| PCVX Vaxcyte, Inc. | 66/100 | — | 81/100 | 53/100 | 0.79 | 56.19% | ONC vs PCVX |
| PGEN Precigen, Inc. | 55/100 | 63/100 | 55/100 | 31/100 | 0.57 | 85.43% | ONC vs PGEN |
| PRAX Praxis Precision Medicines, Inc. | 57/100 | — | 48/100 | 47/100 | 1.13 | 75.11% | ONC vs PRAX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ONC: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ONC
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ONC
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ONC Stock FAQ
What is ONC stock price today?
BeOne Medicines AG's current stock price is $416.54. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ONC bullish or bearish right now?
ONC's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ONC's market cap?
ONC's market cap is $47.36B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ONC's current P/E ratio?
ONC's current P/E ratio is 66.97 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ONC's RSI?
ONC's 14-day RSI is 67.46 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ONC above its 50-day and 200-day moving averages?
ONC is 12.83% from its 50-day SMA and 27.07% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ONC's next earnings date?
ONC's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ONC pay a dividend?
ONC's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.